Contact Information

Available for logged-in reporters only

Newswise DALLAS August 14, 2014 UTSouthwestern Medical Center researchers successfully used a new gene editing method to correct a mutation that leads to Duchenne muscular dystrophy (DMD) in a mouse model of the condition.

Researchers used a technique called CRISPR/Cas9-mediated genome editing, which can precisely remove a mutation in DNA, allowing the bodys DNA repair mechanisms to replace it with a normal copy of the gene. The benefit of this approach over other gene therapy techniques is that the new method can permanently correct the defect in a gene rather than just transiently adding a functional one, said Dr. Eric Olson, Director of the Hamon Center for Regenerative Science and Medicine at UTSouthwestern and Chairman of Molecular Biology.

Using CRISPR/Cas9, the Hamon Center team was able to correct the genetic defect in a mouse model of DMD and thus prevent the development of features of the disease, which in boys causes progressive muscle weakness and degeneration, often along with breathing and heart complications.

Our findings show that CRISPR/Cas9 can correct a genetic mutation that leads to DMD, at least in mice, said Dr. Olson, holder of the Pogue Distinguished Chair in Research on Cardiac Birth Defects, the Robert A. Welch Distinguished Chair in Science, and the Annie and Willie Nelson Professorship in Stem Cell Research. Even in mice with only a small percentage of corrected cells, we saw widespread and progressive improvement of the condition over time, likely reflecting a survival advantage of the corrected cells and their contribution to regenerating muscle. He also pointed out this research sets the stage for possible clinical application of the approach in the future. Skeletal muscle is one of the largest tissues in the human body and current gene therapy methods are only able to affect a portion of the muscle. If the corrected tissue can replace the diseased muscle, then patients may get greater clinical benefit.

Although the genetic cause of DMD has been known for nearly 30 years, there are no treatments that can cure the condition. Duchenne muscular dystrophy breaks down muscle fibers and replaces them with fibrous and/or fatty tissue causing the muscle to gradually weaken.

DMD affects an estimated 1 in 3,6006,000 male births in the United States, according to the Centers for Disease Control (CDC). Left untreated, those with DMD eventually require use of a wheelchair between age 8 and 11, and have a life expectancy of 25 years. Initial symptoms include difficulty running and jumping, and delays in speech development. DMD can be detected through high levels of a protein called creatine kinase in the blood stream, and is confirmed by genetic testing.

Genome editing through the CRISPR/Cas9 system is not currently feasible in humans. However, it may be possible, through advances in the technology, to develop therapies for DMD in the future, Dr. Olson said.

At the moment, we still need to overcome technical challenges, in particular to find better ways to deliver CRISPR/Cas9 to the target tissue and to scale up, Dr. Olson said. But in the future we might be able to use this technique therapeutically, for example to directly target and correct a mutation in muscle stem cells and muscle fibers. We are working on a more clinically feasible method to correct mutations in adult tissues, and have made some progress added Chengzu Long, a graduate student in the Olson lab.

Read the rest here:
New Gene Editing Method Shows Promising Results for Correcting Muscular Dystrophy

Comments are closed.